Gene treatment medicine for hyperuricemia

A technology of gene medicine and uric acid, applied in gene therapy, drug combination, microorganism, etc., can solve the problem of low immunogenicity

Active Publication Date: 2020-05-01
BEIJING GENECRADLE PHARM CO LTD
View PDF5 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

One, the AAV vector only retains the two ITR sequences required for packaging in the wild-type virus, and does not contain protein-coding genes in the wild-type virus genome (Salgenik M, et al . Microbiol Spectr. 2015; 3(4).), low immunogenicity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Gene treatment medicine for hyperuricemia
  • Gene treatment medicine for hyperuricemia
  • Gene treatment medicine for hyperuricemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0062] Example 1 Plasmid vector construction

[0063] In order to construct the pscAAV-CAG-SUO and pscAAV-CAG-SPEG plasmids required for packaging recombinant AAV viruses, we first replaced the pAAV2neo vector with the self-designed CAG promoter (SEQ ID No.9) based on the pAAV2neo preserved by the company In the CMV promoter, replace one side of the ITR sequence in the pAAV2neo vector with a mutated ITR sequence (named ΔITR) (SEQ ID No.13) that deletes the trs (terminal resolution site) and D sequence in the ITR of AAV2, and obtains pscAAV-CAG vector. Next, the artificially synthesized SUO sequence and SPEG sequence were cloned between the KpnI and EcoRI double restriction sites of the pscAAV-CAG vector to obtain the pscAAV-CAG-SUO vector and the pscAAV-CAG-SPEG vector.

[0064] (1) Construction of pscAAV-CAG-SUO vector

[0065] A human-designed secretory urate oxidase sequence SUO. The secretion signal peptide of SUO protein is derived from human Cystatin S protein (SEQ ID...

Embodiment 2

[0068] Example 2 Preparation and assay of recombinant AAV virus

[0069] References (Xiao X, et al . J Virol. 1998;72(3):2224-2232.), the three-plasmid packaging system was used to package the recombinant AAV virus, and the cesium chloride density gradient centrifugation method was used to separate, purify and package the AAV virus. Briefly, AAV vector plasmids (pscAAV-CAG-EGFP, pscAAV-CAM-AUO, pscAAV-CAG-SUO, pscAAV-CAG-SPEG), helper plasmids (pHelper) and AAV Rep and Cap protein expression plasmids (pAAV-R2C1 , pAAV-RC, pAAV-R2C6, pAAV-R2C8 or pAAV-R2C9) were mixed according to the molar ratio of 1:1:1, and transfected into HEK293 cells by the calcium phosphate method. After 48 hours of transfection, the cells and culture supernatant were harvested , application of cesium chloride density gradient centrifugation to separate and purify the recombinant AAV virus. Packaged and purified to obtain scAAV1-CAG-EGFP, scAAV1-CAM-AUO, scAAV1-CAG-SUO, scAAV1-CAG-SPEG, scAAV2-CAG-EGFP...

Embodiment 3

[0075] Example 3 Detection of urate oxidase concentration in the supernatant of recombinant virus infected cells

[0076] 293T cells, primary hepatocytes and MSC cells were mixed at 1×10 6 One per well was spread in a 6-well plate, and four different recombinant AAV viruses scAAV2-CAG-EGFP, scAAV2-CAM-AUO, scAAV2-CAG-SUO, scAAV2-CAG-SPEG were used at MOI=10 5 infected cells. The supernatant was collected 72 hours after infection, and the content of urate oxidase in the serum was measured using the urate oxidase detection kit Amplex Red Uric Acid / Uricase Assay Kit (Life technologies). For the operation process, refer to the kit instruction manual. from Figure 5 It can be seen from the results that, compared with cells infected with scAAV2-CAG-EGFP virus, the supernatant of cells infected with scAAV2-CAM-AUO, scAAV2-CAG-SUO, and scAAV2-CAG-SPEG viruses all have the expression of uric acid oxidase , and the expression of the scAAV2-CAG-SUO and scAAV2-CAG-SPEG groups is better...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a recombinant adeno-associated virus mediated hyperuricemia treatment medicine. A recombinant adeno-associated virus carrier carries an artificially designed urate oxidase geneexpression frame. In-vivo experiment shows that the recombinant adeno-associated virus carrier can be efficiently led into a body, then urate oxidase can be continuously and stably expressed, the content of uric acid can be reduced, and gout symptoms caused by excessive uric acid in blood can be effectively relieved. Results show that the recombinant adeno-associated virus carrier has the potential of being developed into a novel hyperuricemia treatment medicine.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to a hyperuricemia gene therapy drug carrying an artificially designed urate oxidase gene expression frame with a recombinant adeno-associated virus vector. Background technique [0002] With the improvement of economic level and the change of people's lifestyle and dietary structure, the incidence of gout and hyperuricemia is increasing year by year worldwide (Guo Lixin. Drug Evaluation. 2014; 11(1): 21-23. Weaver AL. Cleve Clin J Med. 2008;75(s5):s9-s12.). Hyperuricemia is caused by the disorder of purine metabolism leading to increased production of uric acid and / or decreased excretion, which makes the concentration of uric acid in the blood higher than the normal range. It is the biochemical basis of the pathogenesis of gout (Zhang Yumei, et al. Medical Review. 2012;18( 15): 2441-2444.), the clinical diagnosis standard is under normal purine diet, male blood uric acid content> 4...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/62C12N9/06A61K48/00A61P19/06
CPCC12N9/0048C12Y107/03003A61K48/005A61K48/0025A61P19/06C07K2319/02C12N2750/14143
Inventor 田文洪董小岩马思思
Owner BEIJING GENECRADLE PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap